Life sciences shop Bioscribe works the PR beat for NanoString, the Seattle genomics company slating an initial public offering.
NanoString wants to use proceeds from a share sale to "commercialize" its Prosigna gene analysis, which estimates a patient's risk for recurrence of breast cancer.
NanoString filed its IPO statement May 20 indicating a share sale potentially worth more than $86M. The company reported revenue of $23M in 2012 on a net loss of $17.7M. Its accumulated deficit as of March is nearly $103M.
Bioscribe, which specializes in biotech PR, is based in the Bay Area. It was founded by Ketchum alum Nicole Litchfield. Maruissa Messier, a former Chandler Chicco Companies hand based in San Diego, handles the NanoString account.
Prosigna launched in Europe and Israel and February. NanoString filed an application with the FDA approval in December. The company also wants to expand use of its nCounter Analysis System used in research and clinical settings.
Have a comment? Send it to 
No comments have been submitted for this story yet.